GLP-1 receptor agonists and dual/triple co-agonists were associated with reduced risk of atrial fibrillation in T2D and obesity, potentially through anti-inflammatory and cardiac remodeling mechanisms.
Heart rhythm protectedGLP-1 drugs reduce not just heart attacks and strokes, but also atrial fibrillation — the most common heart rhythm disorder causing strokes
What the researchers found
GLP-1 RAs and GLP-1/GIP/glucagon co-agonists associated with reduced atrial fibrillation risk in T2D and obesity through anti-inflammatory and cardiac remodeling mechanisms.
Why it matters
AF affects 60 million people globally and is the leading cause of stroke. A medication that both treats diabetes/obesity AND prevents AF would be transformative.
How the study worked
Systematic review of GLP-1 RA and co-agonist effects on atrial fibrillation risk in T2D and obesity populations.
What this study cannot tell us
Mostly observational evidence. Cannot prove causation. AF detection methods vary.
How to read the evidence
Systematic review of multiple studies. Consistent association.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs protect the heart's rhythm as well as its vessels — adding arrhythmia prevention to their cardiovascular benefit portfolio.
Questions still open
- Should GLP-1 drugs be recommended for AF prevention?
- Does AF reduction contribute to the MACE benefit of GLP-1 drugs?
- Which patients at AF risk benefit most from GLP-1 therapy?
Common questions
Can GLP-1 drugs prevent irregular heartbeat?
Does this matter beyond diabetes?
Read the original research
Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials.
Metabolism: clinical and experimental, 175, 156463
Citation
Karakasis, Paschalis; Vlachos, Konstantinos; Antoniadis, Antonios P; Siontis, Konstantinos C; Patoulias, Dimitrios; Fragakis, Nikolaos; Mantzoros, Christos S. (2026). Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials.. Metabolism: clinical and experimental, 175, 156463. https://doi.org/10.1016/j.metabol.2025.156463